People · Operator
Named in public records as an officer, director or promoter · active 2025–2025 · Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Juvena Therapeutics, Inc. | — | Pharma | Series B | $34.8M | $144.4M | 2025 |
Christopher Kirk at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Christopher Kirk on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Steven James | 1 | 3 |
| Laura Lande-Diner | 1 | 2 |
| Stephen Juelsgaard | 1 | 2 |
| Jeremy O'Connell | 1 | 1 |
| Hanadie Yousef | 1 | 1 |
| Ben Hemani | 1 | 1 |
| Ayman AlAbdallah | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.